查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980194

生物製药市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Biopharmaceuticals Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

生物製药市场的成长要素

受慢性病盛行率上升、人口老化以及生物製药和先进治疗方法的强劲创新推动，全球生物製药市场持续稳定扩张。预计2025年市场规模将达到6,664.1亿美元，从2026年的7,207.2亿美元成长至2034年的1.41,148兆美元，2026年至2034年的复合年增长率（CAGR）为8.6%。

到 2025 年，北美将在全球市场占据主导地位，市场份额达到 50.37%，这得益于其健全的保险报销制度、较高的诊断率以及先进生物製药的快速普及。

生物製药是利用生物技术，以生物来源的原料为原料生产的复杂药物。这些药物包括蛋白质、单株抗体、核酸、疫苗、荷尔蒙以及细胞和基因疗法。由于人口老化和慢性病负担日益加重，全球对生物製药的需求正在显着增长。

新冠疫情的影响

新冠疫情期间，市场呈现强劲成长态势。新冠疫苗和治疗药物的快速研发、核准和全球分发显着推动了2021年的销售成长。监管政策的灵活性和紧急核准也加快了产品上市速度。

自 2023 年以来，随着 COVID-19 病例数量的下降，市场已转向稳步增长，这得益于强大的候选药物研发管线以及癌症、免疫学和罕见疾病领域核准数量的增加。

市场趋势

新兴地区强劲的管道建设

亚太地区正崛起为临床试验中心，占全球临床活动的近50%（Cytel，2023）。光是中国就占该地区I期临床试验的近40%。一个主要趋势是，中国生物技术公司越来越多地将早期癌症治疗技术授权给全球製药公司。

CAR-T疗法研发管线中的候选药物数量激增。截至2023年3月，ClinicalTrials.gov网站列出了443个CAR-T疗法研发管线候选药物，而2012年仅有12个。随着先进治疗方法获得监管部门核准的增加，竞争格局正在重塑。

市场成长要素

慢性病盛行率上升

慢性病给全球健康带来沉重负担。根据世界卫生组织（WHO，2023）统计，每年有4,100万人死于非传染性疾病，占全球死亡总数的74%。诊断率的提高和公众意识的增强正在推动对创新生物製药的需求。

单株抗体的核准增加

单株抗体仍然是主要的成长要素。 2020年至2021年间，监管机构核准了97种单株抗体，此外还有基因疗法、荷尔蒙和疫苗。癌症和自体免疫疾病治疗药物的加速核准继续推动市场扩张。

抑制因子

高昂的药物研发和治疗成本

生物製药的研发需要大量资金。根据世界卫生组织（WHO）2022年的估计，研发新药的成本在4,340万美元到42亿美元之间。

此外，CAR-T疗法等先进治疗方法极为昂贵。例如，一个疗程的CAR-T疗法费用约为47.5万美元。高昂的价格可能导致某些地区患者难以获得这些疗法，并延缓其推广应用。

市场区隔分析

按类型

市场区隔将产品分为免疫调节剂、疫苗、荷尔蒙、酵素和其他。

  • 2024 年，免疫调节剂占据市场主导地位，在单株抗体和细胞激素疗法核准的推动下，预计到 2026 年，免疫调节剂将占据 54.01% 的市场份额。
  • 在常规免疫计划和新疫苗核准的支持下，到 2024 年，疫苗将占第二大份额。
  • 荷尔蒙类药物市场的成长主要受糖尿病盛行率上升的推动。截至2023年，全球已有5.37亿人患有糖尿病。
  • 酵素和感染疾病物的成长稳定，但速度相对较慢。

透过使用

应用领域包括肿瘤学、循环系统、呼吸内科、免疫学和神经病学。

  • 预计肿瘤领域将在2024年成为市场成长的主要驱动力，并在2026年占据45.3%的市场份额。主要原因是癌症发生率的上升。
  • 呼吸系统领域占据了第二大市场。
  • 随着针对自体免疫疾病的在研药物核准，免疫学领域预计将以第二高的复合年增长率成长。
  • 神经病学和循环系统正呈现稳定但缓慢的增长。

透过分销管道

这些细分市场包括医院药局、药局/零售药局和网路药局。

  • 到 2024 年，医院药局将主导向住院病人施用先进生物製药的市场。
  • 预计到 2026 年，药局和零售药局将占市场份额的 35.87%。
  • 由于数位化和宅配服务的进步，预计线上药局将以最高的复合年增长率成长。

区域趋势

北美洲

北美维持领先地位，2025年市场规模达3,356.5亿美元。预计到2026年，美国市场规模将达到3,458亿美元。完善的医保报销机制和抗癌药物的广泛普及是推动该地区成长的主要因素。

欧洲

欧洲占据了相当大的市场。预计到2026年，英国市场规模将达到305.5亿美元，德国市场规模预计将达481.6亿美元。政府资金和战略伙伴关係正在支持市场扩张。

亚太地区

预计亚太地区将以最高的复合年增长率成长。到2026年：

  • 日本：173.4亿美元
  • 中国：410.7亿美元
  • 印度：79.6亿美元

临床试验数量的增加、监管核准的增加以及患者意识的提高正在推动该地区的成长。

世界其他地区

由于基础设施的限制，拉丁美洲、中东和非洲地区的复合年增长率预计将相对较低，但医疗保健系统的改善正在逐步支持扩张。

主要企业

全球市场主要企业包括以下几家：

  • 辉瑞
  • 艾伯维
  • 百时美施贵宝
  • 强生服务
  • 拜耳股份公司
  • 礼来
  • 赛诺菲
  • 默克公司
  • F. Hoffmann-La Roche 有限公司
  • 诺华公司
  • GSK plc
  • 武田药品工业株式会社

在新冠肺炎疫情期间，辉瑞公司凭藉强劲的疫苗销售占据了市场主导地位。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要疾病流行情形：依主要国家划分，2025 年
  • 新产品发布：按主要企业划分
  • 关键产业趋势－併购与合作
  • 主要国家的监管状况
  • 主要企业管道分析
  • 新冠疫情对市场的影响

第五章：2021-2034年全球生物製药市场分析、洞察与预测

  • 市场分析、洞察与预测：按类型
    • 免疫调节剂
      • 单株抗体
      • 细胞激素
      • 干扰素
      • 其他的
    • 酵素
      • 水解酵素
      • 解离酶
      • 氧化还原酶
      • 其他的
    • 疫苗
      • 重组/组合/次单元
      • 失活
      • 减毒活病毒疫苗
      • 类毒素
    • 荷尔蒙
      • 人体生长荷尔蒙
      • 胰岛素
      • 甲状腺刺激素
      • 其他的
    • 其他的
  • 市场分析、洞察与预测：按应用领域划分
    • 循环系统
    • 肿瘤学
    • 呼吸系统
    • 免疫学
    • 神经病学
    • 其他的
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 药局和零售药房
    • 网路药房
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美生物製药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲生物製药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太生物製药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲生物製药市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲生物製药市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Pfizer Inc.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Lilly
    • Sanofi
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • GSK plc
    • Takeda Pharmaceutical Company Limited.
Product Code: FBI106928

Growth Factors of biopharmaceuticals Market

The global biopharmaceuticals market continues to expand steadily, supported by rising chronic disease prevalence, increasing geriatric population, and strong innovation in biologics and advanced therapies. The market was valued at USD 666.41 billion in 2025 and is projected to grow from USD 720.72 billion in 2026 to USD 1,411.48 billion by 2034, registering a CAGR of 8.6% during 2026-2034.

In 2025, North America dominated the global market with a 50.37% share, driven by strong reimbursement systems, high diagnosis rates, and rapid adoption of advanced biologics.

Biopharmaceuticals are complex medicines derived from biological sources using biotechnology. These include proteins, monoclonal antibodies, nucleic acids, vaccines, hormones, and cell and gene therapies. Growing aging populations and the rising burden of chronic diseases are significantly increasing global demand.

COVID-19 Impact

The market experienced strong positive growth during the COVID-19 pandemic. The rapid development, approval, and global distribution of COVID-19 vaccines and therapeutics significantly boosted revenues in 2021. Regulatory flexibility and emergency approvals accelerated product launches.

From 2023 onward, as COVID-19 cases declined, the market transitioned toward steady growth driven by robust pipeline candidates and increasing approvals across oncology, immunology, and rare diseases.

Market Trends

Strong Pipeline Development in Emerging Regions

Asia Pacific has emerged as a clinical trial hub, accounting for nearly 50% of global clinical activity (Cytel, 2023). China alone contributes nearly 40% of Phase I trials in the region. Increasing licensing of early-stage cancer therapies from Chinese biotech firms to global pharmaceutical companies is a key trend.

The number of CAR-T therapy pipeline candidates has surged significantly. In March 2023, 443 CAR-T pipeline candidates were listed on ClinicalTrials.gov, compared to only 12 in 2012. Growing regulatory approvals for advanced therapies are reshaping the competitive landscape.

Market Growth Drivers

Rising Prevalence of Chronic Diseases

Chronic diseases are a major global health burden. According to WHO (2023), 41 million deaths annually are attributed to non-communicable diseases, accounting for 74% of global deaths. Rising diagnosis rates and awareness programs are increasing demand for innovative biologics.

Increasing Approvals for Monoclonal Antibodies

Monoclonal antibodies remain a major growth driver. Between 2020 and 2021, regulatory agencies approved 97 monoclonal antibodies, along with gene therapies, hormones, and vaccines. Accelerated approvals for oncology and autoimmune treatments continue to fuel market expansion.

Restraining Factors

High Drug Development and Treatment Costs

Biopharmaceutical development is capital-intensive. WHO (2022) estimates the cost of developing a new drug ranges between USD 43.4 million and USD 4.2 billion.

Additionally, advanced therapies such as CAR-T treatments are highly expensive. For example, one treatment cycle of CAR-T therapy can cost approximately USD 475,000. High pricing may limit accessibility and slow adoption in certain regions.

Market Segmentation Analysis

By Type

The market is segmented into immunomodulators, vaccines, hormones, enzymes, and others.

  • Immunomodulators dominated in 2024 and are projected to hold 54.01% share in 2026, driven by monoclonal antibody approvals and cytokine therapies.
  • Vaccines held the second-largest share in 2024, supported by routine immunization programs and new vaccine approvals.
  • The hormone segment growth is driven by rising diabetes prevalence. In 2023, 537 million people were living with diabetes globally.
  • Enzymes and anti-infectives contribute steady but comparatively moderate growth.

By Application

Applications include oncology, cardiology, respiratory, immunology, neurology, and others.

  • Oncology dominated the market in 2024 and is projected to account for 45.3% share in 2026. Rising cancer incidence is a primary factor.
  • The respiratory segment held the second-largest share.
  • Immunology is expected to grow at the second-highest CAGR due to pipeline approvals for autoimmune diseases.
  • Neurology and cardiology show moderate but steady growth.

By Distribution Channel

Segments include hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

  • Hospital pharmacies dominated in 2024 due to inpatient administration of advanced biologics.
  • Drug stores & retail pharmacies are projected to contribute 35.87% share in 2026.
  • Online pharmacies are expected to grow at the highest CAGR due to digital adoption and doorstep delivery services.

Regional Insights

North America

North America generated USD 335.65 billion in 2025, maintaining its leadership. The U.S. market is projected to reach USD 345.8 billion by 2026. Strong reimbursement frameworks and high oncology drug adoption drive regional growth.

Europe

Europe holds a substantial market share. The UK market is projected to reach USD 30.55 billion by 2026, while Germany is expected to reach USD 48.16 billion by 2026. Government funding and strategic partnerships support expansion.

Asia Pacific

Asia Pacific is projected to grow at the highest CAGR. By 2026:

  • Japan: USD 17.34 billion
  • China: USD 41.07 billion
  • India: USD 7.96 billion

Rising clinical trials, regulatory approvals, and growing patient awareness fuel regional growth.

Rest of the World

Latin America and the Middle East & Africa are expected to grow at a comparatively lower CAGR due to infrastructure limitations but improving healthcare systems are gradually supporting expansion.

Key Industry Players

Leading companies shaping the global market include:

  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Eli Lilly
  • Sanofi
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • GSK plc
  • Takeda Pharmaceutical Company Limited

Pfizer Inc. dominated the market during the COVID-19 period due to strong vaccine sales performance.

Conclusion

The global biopharmaceuticals market is projected to expand from USD 666.41 billion in 2025 to USD 1,411.48 billion by 2034, growing at a CAGR of 8.6% during 2026-2034. Rising chronic disease prevalence, increasing monoclonal antibody approvals, and robust pipeline development-particularly in oncology and immunology-are key growth drivers. While high development and treatment costs remain a challenge, expanding clinical research, technological innovation, and strong regional investments, especially in North America and Asia Pacific, are expected to sustain long-term market growth.

Segmentation By Type

  • Immunomodulators
    • Monoclonal Antibodies
    • Cytokines
    • Interferons
    • Others
  • Enzymes
    • Hyrdolases
    • Lyases
    • Oxidoreductases
    • Others
  • Vaccines
    • Recombinant/Conjugate/Subunit
    • Inactivated
    • Live Attenuated
    • Toxoid
  • Hormones
    • Human Growth Hormones
    • Insulin
    • Thyroid Stimulating Hormones
    • Others
  • Others

By Application

  • Cardiology
  • Oncology
  • Respiratory
  • Immunology
  • Neurology
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Type, Application, Distribution Channel, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Type, Application, Distribution Channel, Country, and Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • China (By Application)
    • India (By Application)
    • Japan (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • GCC (By Application)
    • South Africa (By Application)
  • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Regulatory Scenario, By Key Countries/Regions
  • 4.5. Pipeline Analysis, By Key Players
  • 4.6. Impact of COVID-19 on the Market

5. Global Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Immunomodulators
      • 5.1.1.1. Monoclonal Antibodies
      • 5.1.1.2. Cytokines
      • 5.1.1.3. Interferons
      • 5.1.1.4. Others
    • 5.1.2. Enzymes
      • 5.1.2.1. Hyrdolases
      • 5.1.2.2. Lyases
      • 5.1.2.3. Oxidoreductases
      • 5.1.2.4. Others
    • 5.1.3. Vaccines
      • 5.1.3.1. Recombinant/Conjugate/Subunit
      • 5.1.3.2. Inactivated
      • 5.1.3.3. Live Attenuated
      • 5.1.3.4. Toxoid
    • 5.1.4. Hormones
      • 5.1.4.1. Human Growth Hormones
      • 5.1.4.2. Insulin
      • 5.1.4.3. Thyroid Stimulating Hormones
      • 5.1.4.4. Others
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Cardiology
    • 5.2.2. Oncology
    • 5.2.3. Respiratory
    • 5.2.4. Immunology
    • 5.2.5. Neurology
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Drug Stores & Retail Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Immunomodulators
      • 6.1.1.1. Monoclonal Antibodies
      • 6.1.1.2. Cytokines
      • 6.1.1.3. Interferons
      • 6.1.1.4. Others
    • 6.1.2. Enzymes
      • 6.1.2.1. Hyrdolases
      • 6.1.2.2. Lyases
      • 6.1.2.3. Oxidoreductases
      • 6.1.2.4. Others
    • 6.1.3. Vaccines
      • 6.1.3.1. Recombinant/Conjugate/Subunit
      • 6.1.3.2. Inactivated
      • 6.1.3.3. Live Attenuated
      • 6.1.3.4. Toxoid
    • 6.1.4. Hormones
      • 6.1.4.1. Human Growth Hormones
      • 6.1.4.2. Insulin
      • 6.1.4.3. Thyroid Stimulating Hormones
      • 6.1.4.4. Others
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Cardiology
    • 6.2.2. Oncology
    • 6.2.3. Respiratory
    • 6.2.4. Immunology
    • 6.2.5. Neurology
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Drug Stores & Retail Pharmacies
    • 6.3.3. Online Pharmacies
    • 6.3.4. Other Facilities
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Immunomodulators
      • 7.1.1.1. Monoclonal Antibodies
      • 7.1.1.2. Cytokines
      • 7.1.1.3. Interferons
      • 7.1.1.4. Others
    • 7.1.2. Enzymes
      • 7.1.2.1. Hyrdolases
      • 7.1.2.2. Lyases
      • 7.1.2.3. Oxidoreductases
      • 7.1.2.4. Others
    • 7.1.3. Vaccines
      • 7.1.3.1. Recombinant/Conjugate/Subunit
      • 7.1.3.2. Inactivated
      • 7.1.3.3. Live Attenuated
      • 7.1.3.4. Toxoid
    • 7.1.4. Hormones
      • 7.1.4.1. Human Growth Hormones
      • 7.1.4.2. Insulin
      • 7.1.4.3. Thyroid Stimulating Hormones
      • 7.1.4.4. Others
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Cardiology
    • 7.2.2. Oncology
    • 7.2.3. Respiratory
    • 7.2.4. Immunology
    • 7.2.5. Neurology
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Drug Stores & Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Application
    • 7.4.2. Germany
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Italy
      • 7.4.4.1. By Application
    • 7.4.5. Spain
      • 7.4.5.1. By Application
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Application
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Application

8. Asia Pacific Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Immunomodulators
      • 8.1.1.1. Monoclonal Antibodies
      • 8.1.1.2. Cytokines
      • 8.1.1.3. Interferons
      • 8.1.1.4. Others
    • 8.1.2. Enzymes
      • 8.1.2.1. Hyrdolases
      • 8.1.2.2. Lyases
      • 8.1.2.3. Oxidoreductases
      • 8.1.2.4. Others
    • 8.1.3. Vaccines
      • 8.1.3.1. Recombinant/Conjugate/Subunit
      • 8.1.3.2. Inactivated
      • 8.1.3.3. Live Attenuated
      • 8.1.3.4. Toxoid
    • 8.1.4. Hormones
      • 8.1.4.1. Human Growth Hormones
      • 8.1.4.2. Insulin
      • 8.1.4.3. Thyroid Stimulating Hormones
      • 8.1.4.4. Others
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Cardiology
    • 8.2.2. Oncology
    • 8.2.3. Respiratory
    • 8.2.4. Immunology
    • 8.2.5. Neurology
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores & Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. China
      • 8.4.1.1. By Application
    • 8.4.2. India
      • 8.4.2.1. By Application
    • 8.4.3. Japan
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Immunomodulators
      • 9.1.1.1. Monoclonal Antibodies
      • 9.1.1.2. Cytokines
      • 9.1.1.3. Interferons
      • 9.1.1.4. Others
    • 9.1.2. Enzymes
      • 9.1.2.1. Hyrdolases
      • 9.1.2.2. Lyases
      • 9.1.2.3. Oxidoreductases
      • 9.1.2.4. Others
    • 9.1.3. Vaccines
      • 9.1.3.1. Recombinant/Conjugate/Subunit
      • 9.1.3.2. Inactivated
      • 9.1.3.3. Live Attenuated
      • 9.1.3.4. Toxoid
    • 9.1.4. Hormones
      • 9.1.4.1. Human Growth Hormones
      • 9.1.4.2. Insulin
      • 9.1.4.3. Thyroid Stimulating Hormones
      • 9.1.4.4. Others
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Cardiology
    • 9.2.2. Oncology
    • 9.2.3. Respiratory
    • 9.2.4. Immunology
    • 9.2.5. Neurology
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores & Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Immunomodulators
      • 10.1.1.1. Monoclonal Antibodies
      • 10.1.1.2. Cytokines
      • 10.1.1.3. Interferons
      • 10.1.1.4. Others
    • 10.1.2. Enzymes
      • 10.1.2.1. Hyrdolases
      • 10.1.2.2. Lyases
      • 10.1.2.3. Oxidoreductases
      • 10.1.2.4. Others
    • 10.1.3. Vaccines
      • 10.1.3.1. Recombinant/Conjugate/Subunit
      • 10.1.3.2. Inactivated
      • 10.1.3.3. Live Attenuated
      • 10.1.3.4. Toxoid
        • 10.1.3.4.1. Hormones
          • 10.1.3.4.1.1. Human Growth Hormones
          • 10.1.3.4.1.2. Insulin
          • 10.1.3.4.1.3. Thyroid Stimulating Hormones
          • 10.1.3.4.1.4. Others
        • 10.1.3.4.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Cardiology
    • 10.2.2. Oncology
    • 10.2.3. Respiratory
    • 10.2.4. Immunology
    • 10.2.5. Neurology
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Drug Stores & Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Application
    • 10.4.2. South Africa
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis ( 2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. AbbVie Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bristol-Myers Squibb Company
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Johnson & Johnson Services, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Lilly
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sanofi
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Merck & Co., Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. F. Hoffmann-La Roche Ltd
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Novartis AG
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. GSK plc
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Takeda Pharmaceutical Company Limited.
      • 11.2.12.1. Overview
      • 11.2.12.2. Products & Services
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 02: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 03: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 04: Global Biopharmaceuticals Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 05: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 06: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 07: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 08: North America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: U.S. Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 10: Canada Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 12: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 13: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 14: Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: U.K. Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 16: Germany Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 17: France Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 18: Italy Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: Spain Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 20: Scandinavia Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 21: Rest of Europe Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 22: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 23: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 24: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: China Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 27: India Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 28: Japan Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 29: Australia Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 30: Southeast Asia Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 31: Rest of Asia Pacific Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 32: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 33: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 34: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 35: Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 37: Mexico Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 38: Rest of Latin America Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 39: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 40: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 41: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: GCC Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 44: South Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 45: Rest of Middle East & Africa Biopharmaceuticals Market Revenue (USD billion) Forecast, By Application, 2021-2034

List of Figures

  • Figure 01: Global Biopharmaceuticals Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Biopharmaceuticals Market Value Share (%), by Type, 2025 & 2034
  • Figure 03: Global Biopharmaceuticals Market Value Share (%), by Application, 2025 & 2034
  • Figure 04: Global Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 05: Global Biopharmaceuticals Market Value (USD billion), by Region, 2025 & 2034
  • Figure 06: North America Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 07: North America Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 08: North America Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 09: North America Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 10: North America Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 11: North America Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 12: North America Biopharmaceuticals Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Biopharmaceuticals Market Value Share (%), By Country, 2025
  • Figure 14: Europe Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 15: Europe Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 16: Europe Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 17: Europe Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 18: Europe Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 19: Europe Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 20: Europe Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 23: Asia Pacific Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 24: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 25: Asia Pacific Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 26: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 28: Asia Pacific Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 31: Latin America Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 32: Latin America Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 33: Latin America Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 34: Latin America Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 36: Latin America Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Type, 2025 & 2034
  • Figure 39: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Type, 2025
  • Figure 40: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Application, 2025 & 2034
  • Figure 41: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Application, 2025
  • Figure 42: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Distribution Channel, 2025
  • Figure 44: Middle East & Africa Biopharmaceuticals Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Biopharmaceuticals Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Biopharmaceuticals Market Share (%), By Company, 2025